SCHEMBL19848314

SCHEMBL19848314

C=CCn1cnc2cc(C)ccc21

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
HSD17B10 Q99714 3/20 0.47
MAPT P10636 3/20 0.47
KDM4E B2RXH2 2/20 0.47
HPGD P15428 1/20 0.47
FGFR1 P11362 1/20 0.46
TNF P01375 1/20 0.44
CYP11B1 P15538 3/20 0.42
CYP11B2 P19099 3/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
TBXA2R P21731 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK1 P28482 1/20 0.40
GAA P10253 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19848085 0.87 TNF (0.44) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL10893089 0.81 NPC1 (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL6536735 0.81 PRPS1 (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL10891799 0.81 MAPT (0.41) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL623907 0.81 MAPT (0.64) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL1539099 0.81 FGFR1 (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL7643046 0.80 FGFR1 (0.50) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL4563259 0.80 KMT2A (0.50) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL19911317 0.80 POLB (0.58) ALDH1A1NPC1RAB9AMAPTLMNA
SCHEMBL10600757 0.80 NPC1 (0.62) ALDH1A1NPC1RAB9ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-08-25 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2018-03-01 US disclosed
EP-3279997-A1 NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY Asahi Kasei Kabushiki Kaisha (JP) 2018-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10756394-B2 Nonaqueous electrolyte and nonaqueous secondary battery BPTF, BRD4, KCNN2 ALDH1A1 3497/4885NPC1 2529/4885RAB9A 3611/4885
US-20180062213-A1 Nonaqueous Electrolyte and Nonaqueous Secondary Battery BPTF, BRD4, KCNN2 ALDH1A1 3497/4885NPC1 2529/4885RAB9A 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.